Table 2.
Variable | Regression Coefficient (mm) |
95% CI | p |
---|---|---|---|
BASELINE MODEL | |||
Age ( per SD of 10 yrs) 1 | 1.2 | 1.1–1.3 | <0.001 |
Gender 2 | 1.9 | 1.6–2.1 | <0.001 |
Body Surface Area (per SD of 0.23m2)3 | 1.0 | 0.9–1.1 | <0.001 |
BASELINE MODEL+ ONE VARIABLE | |||
Traditional Risk Factors | |||
Race | |||
…Caucasian | Reference | Reference | |
Chinese American | 1.7 | 1.3–2.1 | <0.001 |
African American | −0.2 | −0.4-0.1 | 0.20 |
Hispanic | 0.1 | −0.2–0.4 | 0.57 |
Systolic BP (per SD of 21 mmHg)4 | 0.3 | 0.2–0.5 | <0.001 |
Diastolic BP (per SD of 10 mmHg)4 | 0.7 | 0.6–0.8 | <0.001 |
Mean BP (per SD of 13 mmHg) 4 | 0.6 | 0.4–0.7 | <0.001 |
Pulse Pressure (per SD of 17 mmHg) 4 | −0.1 | −0.3-0.0 | 0.07 |
Hypertension (yes) | 0.9 | 0.7–1.2 | <0.001 |
Cigarette Smoking (yes) | −0.2 | −0.4-0.0 | 0.07 |
Diabetes (yes) | −0.4 | −0.8-−0.1 | 0.02 |
Total Cholesterol (per SD of 36 mg/dl)5 | −0.1 | −0.2-0.0 | 0.08 |
HDL (per SD of 15 mg/dl)5 | −0.02 | −0.1-0.1 | 0.74 |
LDL ( per SD of 32 mg/dl)5 | −0.1 | −0.2-0.0 | 0.18 |
Triglycerides ( per SD of 89 mg/dl)5 | −0.04 | −0.2-0.1 | 0.43 |
Measures of Subclinical Atherosclerosis | |||
Coronary Calcium Score (present) | 0.3 | 0.1–0.5 | 0.015 |
Log CAC (per SD of 2.52) | 0.21 | 0.1–0.4 | 0.001 |
Maximum CCA IMT (per SD of 0.19mm) | 0.1 | 0.0–0.3 | 0.06 |
Maximum ICA IMT (per SD of 0.60mm) | −0.1 | −0.2-0.1 | 0.44 |
Systemic Inflammatory Markers | |||
IL-6 (per SD of 1.22pg/ml) | −0.03 | −0.2-0.1 | 0.59 |
CRP (per SD of 6 mg/l) | −0.1 | −0.2-0.0 | 0.17 |
CI: Confidence Interval, BP: blood pressure, CAC: coronary artery calcium score, CCA IMT: common carotid artery intima media thickness, ICA IMT: Internal carotid artery intima media thickness.
All models (except for age, gender and, body surface area) were adjusted for age, gender, body surface area.
Adjusted for gender, body surface area
Adjusted for age, body surface area
Adjusted for age and gender
Adjusted for age, gender, body surface area, hypertension medication use
Adjusted for age, gender, body surface area, lipid lowering medication use.